Menarini group and radius health announce positive phase 3 topline results from the emerald trial evaluating elacestrant in breast cancer

Florence, italy and boston, oct. 20, 2021 (globe newswire) -- the menarini group (“menarini”) and radius health, inc. (“radius”) (nasdaq: rdus) (collectively, the “companies”) today announced positive topline results from the emerald study.

RDUS Ratings Summary

RDUS Quant Ranking